Unveiling Ocular Manifestations in Systemic Lupus ErythematosusReview Published on 2024-02-122024-09-05 Journal: Journal of Clinical Medicine [Category] update2024, [키워드] Autoimmune Corticosteroids lupus erythematosus systemic [DOI] 10.3390/jcm13041047 PMC 바로가기 [Article Type] Review
Voclosporin and the Antiviral Effect Against SARS-CoV-2 in Immunocompromised Kidney PatientsClinical Research Published on 2023-09-072024-09-05 Journal: Kidney International Reports [Category] update2024, [키워드] calcineurin inhibitors COVID-19 Kidney transplantation lupus erythematosus lupus nephritis SARS-CoV-2 [DOI] 10.1016/j.ekir.2023.09.003 PMC 바로가기 [Article Type] Clinical Research
SARS-CoV-2 infection and SLE: endothelial dysfunction, atherosclerosis, and thrombosisarticle Published on 2023-01-092024-09-05 Journal: Clinical Rheumatology [Category] update2024, [키워드] autoantibodies Endothelium lupus erythematosus Rheumatic diseases SARS-CoV-2; Thrombosis [DOI] 10.1007/s10067-022-06497-1 PMC 바로가기 [Article Type] article
Autoantibodies during infectious diseases: Lessons from malaria applied to COVID-19 and other infections전염병 중 자가항체: 코로나19 및 기타 감염에 적용되는 말라리아의 교훈Article Published on 2022-09-152022-11-15 Journal: Frontiers in Immunology [Category] 말라리아, 진단, [키워드] Anemia antigens applied Atypical atypical B cells autoantibodies autoantibody Autoimmune autoimmune disorder Autoimmune disorders Autoimmunity B cell B cells cellular correlated COVID-19 Cytokines Diseases dsDNA Evidence explain highlighting immune immune response Infection infections Infectious disease inflammatory disease lesson lipids lupus erythematosus malaria malarial mechanism pathological role pathology reported severe COVID-19 SLE systemic target Topic [DOI] 10.3389/fimmu.2022.938011 PMC 바로가기
Identification of genomic determinants contributing to cytokine release in immunotherapies and human diseases면역 요법 및 인간 질병에서 사이토카인 방출에 기여하는 게놈 결정인자의 식별Article Published on 2022-07-282022-09-11 Journal: Journal of Translational Medicine [Category] Coronavirus, 유전자 메커니즘, [키워드] abrogate Analysis Autoimmune diseases CAR CAR T-cell therapy CD22 cells cellular Cohort cohorts collected contribute contributing to CRS cytokine release Cytokine release syndrome dataset determinant develop driving drugs targeting expression Frequency genomic Glycolysis human disease identification immune system Immunotherapy IMPROVE in vivo Infection Influenza influenza infection influenza infections lupus erythematosus management mRNA not increased occur outcomes pathway Patient patients with influenza PFKFB4 PFKFB4. platform Prevent reaction reduce RNA extraction severity SLE syndrome systemic lupus erythematosus T-cell T-cells targeted therapy therapy tissues Treatment Tumor upregulated was used were used while with COVID-19 [DOI] 10.1186/s12967-022-03531-3 PMC 바로가기 [Article Type] Article
Anifrolumab efficacy and safety by type I interferon gene signature and clinical subgroups in patients with SLE: post hoc analysis of pooled data from two phase III trialsSystemic Lupus Erythematosus Published on 2022-07-252024-09-04 Journal: Annals of the rheumatic diseases [Category] 대상포진, [키워드] biological therapy lupus erythematosus systemic Therapeutics [DOI] 10.1136/annrheumdis-2021-221425 PMC 바로가기 [Article Type] Systemic Lupus Erythematosus
Characteristics associated with poor COVID-19 outcomes in individuals with systemic lupus erythematosus: data from the COVID-19 Global Rheumatology Alliance전신성 홍반성 루푸스가 있는 개인의 COVID-19 결과 불량과 관련된 특성: COVID-19 Global Rheumatology Alliance의 데이터Article Published on 2022-07-012022-09-12 Journal: Annals of the rheumatic diseases [Category] Fulltext, MERS, 진단, [키워드] 95% CI Alliance Characteristics Comorbidities Comorbidity COVID-19 COVID-19 severity Cyclophosphamide death defined demographic characteristics Demographic factors determine Disease activity dose driven by Epidemiology glucocorticoid hospitalised individual Kidney disease lupus erythematosus Male sex medication methotrexate moderate multivariable multivariable model Older age ordinal logistic regression outcome outcomes Oxygenation Prednisone reported severe COVID-19 SLE systemic systemic lupus erythematosus Treatment Ventilation [DOI] 10.1136/annrheumdis-2021-221636 PMC 바로가기 [Article Type] Article
Frequency and severity of COVID-19 in patients with various rheumatic diseases treated regularly with colchicine or hydroxychloroquine콜히친 또는 하이드록시클로로퀸으로 정기적으로 치료받는 다양한 류마티스 질환 환자의 COVID-19 빈도 및 중증도Article Published on 2022-07-012022-09-11 Journal: Journal of medical virology [Category] COVID19(2023년), SARS, 진단, 치료법, [키워드] 95% CI 95% confidence interval acute respiratory syndrome acute respiratory syndrome coronavirus analyzed anti-SARS-CoV-2 IgG Arthritis being Clinical data Colchicine collected Contact control group coronavirus coronavirus disease Coronavirus disease 2019 COVID-19 COVID-19-related symptom COVID-19-related symptoms described disease Famial Mediterranean fever Familial Familial Mediterranean fever FIVE HCQ healthy hospital Hospital admission Hospitalized household contact Hydroxychloroquine IgG Immunoglobulin Immunoglobulin G less Lupus lupus erythematosus Manifestations Mediterranean fever Musculoskeletal nucleocapsid occurred Odds ratio Patient positive prevention of COVID-19 respiratory rheumatic and musculoskeletal disease. rheumatic disease Rheumatoid rheumatoid arthritis seropositive subjects serum sample serum samples severe disease severity of COVID-19 subject syndrome systemic systemic lupus erythematosus the patient treated Treatment [DOI] 10.1002/jmv.27731 PMC 바로가기 [Article Type] Article
Immunogenicity of the third and fourth BNT162b2 mRNA COVID-19 boosters and factors associated with immune response in patients with SLE and rheumatoid arthritis세 번째 및 네 번째 BNT162b2 mRNA COVID-19 부스터 및 SLE 및 류마티스 관절염 환자의 면역 반응과 관련된 인자의 면역원성Article Published on 2022-07-012022-09-11 Journal: Lupus science & medicine [Category] COVID19(2023년), MERS, SARS, 변종, 진단, [키워드] adenoviral vector Administered anti-RBD Anti-RBD IgG Arthritis benefit BNT162b2 BNT162b2 mRNA booster booster dose booster vaccination cellular Cellular immune response COVID-19 domain enrolled evaluate Factor heterogenous humoral Humoral response IgG immune response immunogenicity immunosuppressive inactivated Inactivated vaccine initial Lupus lupus erythematosus Lupus Erythematosus, Systemic mRNA vaccines Neutralising activity occurred omicron Omicron variant Patient positive raised RBD RBD IgG registration number rheumatoid arthritis significantly SLE systemic titre vaccination Vaccine variant was done were given [DOI] 10.1136/lupus-2022-000726 PMC 바로가기 [Article Type] Article
Thrombosis and thrombocytopenia in COVID-19 and after COVID-19 vaccinationCOVID-19 및 COVID-19 백신 접종 후의 혈전증 및 혈소판 감소증Review Published on 2022-07-012022-09-11 Journal: Trends in cardiovascular medicine [Category] COVID19(2023년), SARS, 치료기술, [키워드] ACE2 activate Activation acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 adaptive immune system Adenovirus Adenovirus-vectored vaccine administration aggregation angiotensin angiotensin converting enzyme angiotensin converting enzyme 2 Antibody detection Antiplatelet factor cause Coagulation Coagulopathy condition coronavirus coronavirus disease COVID-19 COVID-19 vaccination Critical detect diagnosing Diagnosis Disease progression disease severity dysregulation effective ELISA enzyme enzyme-linked immunosorbent enzyme-linked immunosorbent assay event false-positive rate false-positive rates hemophagocytic lymphohistiocytosis hemophagocytic syndrome immune Immune thrombocytopenic purpura Inflammation initial Interaction lupus erythematosus Messenger RNA mitigate occur optical optical density Pathogenesis PF4 Platelet platelet aggregation Platelets positive progression purpura SARS-CoV-2 serious complication severe acute respiratory syndrome Coronavirus Side effects Spike protein syndrome systemic lupus erythematosus the disease the patient thrombocytopenia thrombocytopenic purpura Thromboembolism thrombosis thrombotic Thrombotic thrombocytopenia Thrombotic thrombocytopenic purpura vaccination Vaccine Vaccines vectored vaccine [DOI] 10.1016/j.tcm.2022.02.008 PMC 바로가기 [Article Type] Review